Literature DB >> 25640991

Mouse model for pre-clinical study of human cancer immunotherapy.

Zhiya Ya1, Yared Hailemichael2, Willem Overwijk2, Nicholas P Restifo1.   

Abstract

This unit describes protocols for developing tumors in mice, including subcutaneous growth, pulmonary metastases of B16 melanoma, and spontaneous melanoma in B-Raf V600E/PTEN deletion transgenic mouse models. Two immunization methods to prevent B16 tumor growth are described using B16.GM-CSF and recombinant vaccinia virus. A therapeutic approach is also included that uses adoptive transfer of tumor antigen-specific T cells. Methods including CTL induction, isolation, testing, and genetic modification of mouse T cells for adoptive transfer by using retrovirus-expressing genes of interest are provided. Additional sections, including growing B16 melanoma, enumerating pulmonary metastases, tumor imaging technique, and use of recombinant viruses for vaccination, are discussed together with safety concerns.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Keywords:  B16 melanoma; translational cancer immunotherapy; tumor imaging; use of recombinant viruses for vaccination

Mesh:

Substances:

Year:  2015        PMID: 25640991      PMCID: PMC4361407          DOI: 10.1002/0471142735.im2001s108

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  73 in total

1.  Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.

Authors:  W W Overwijk; D R Surman; K Tsung; N P Restifo
Journal:  Methods       Date:  1997-06       Impact factor: 3.608

2.  Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.

Authors:  C Naftzger; Y Takechi; H Kohda; I Hara; S Vijayasaradhi; A N Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.

Authors:  L A Donehower; M Harvey; B L Slagle; M J McArthur; C A Montgomery; J S Butel; A Bradley
Journal:  Nature       Date:  1992-03-19       Impact factor: 49.962

4.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

Authors:  L Chin; J Pomerantz; D Polsky; M Jacobson; C Cohen; C Cordon-Cardo; J W Horner; R A DePinho
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

5.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Prostate cancer in a transgenic mouse.

Authors:  N M Greenberg; F DeMayo; M J Finegold; D Medina; W D Tilley; J O Aspinall; G R Cunha; A A Donjacour; R J Matusik; J M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

7.  Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

Authors:  M B Bloom; D Perry-Lalley; P F Robbins; Y Li; M el-Gamil; S A Rosenberg; J C Yang
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

Authors:  L Chen; P McGowan; S Ashe; J Johnston; Y Li; I Hellström; K E Hellström
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

9.  A reassessment of the role of B7-1 expression in tumor rejection.

Authors:  T C Wu; A Y Huang; E M Jaffee; H I Levitsky; D M Pardoll
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.

Authors:  I Hara; Y Takechi; A N Houghton
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  9 in total

1.  A Listeria-derived polypeptide promotes in vivo activation of NK cells for antitumor therapy.

Authors:  Amber L Ortiz; Laurel L Lenz
Journal:  Immunohorizons       Date:  2017-06-26

2.  Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.

Authors:  Bradley D Shields; Brian Koss; Erin M Taylor; Aaron J Storey; Kirk L West; Stephanie D Byrum; Samuel G Mackintosh; Rick Edmondson; Fade Mahmoud; Sara C Shalin; Alan J Tackett
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

3.  In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model.

Authors:  Cara L Haymaker; Yared Hailemichael; Yi Yang; Roza Nurieva
Journal:  J Vis Exp       Date:  2017-11-28       Impact factor: 1.355

4.  Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy.

Authors:  Sandeep T Koshy; Alexander S Cheung; Luo Gu; Amanda R Graveline; David J Mooney
Journal:  Adv Biosyst       Date:  2017-01-05

5.  An engineered IL-2 partial agonist promotes CD8+ T cell stemness.

Authors:  Fei Mo; Zhiya Yu; Peng Li; Jangsuk Oh; Rosanne Spolski; Liang Zhao; Caleb R Glassman; Tori N Yamamoto; Yun Chen; Filip M Golebiowski; Dalton Hermans; Sonia Majri-Morrison; Lora K Picton; Wei Liao; Min Ren; Xiaoxuan Zhuang; Suman Mitra; Jian-Xin Lin; Luca Gattinoni; Jonathan D Powell; Nicholas P Restifo; K Christopher Garcia; Warren J Leonard
Journal:  Nature       Date:  2021-09-15       Impact factor: 69.504

6.  In Vitro Cell Impedance Assay to Examine Antigen-Specific T-Cell-Mediated Melanoma Cell Killing to Support Cancer Immunotherapy Drug Discovery.

Authors:  Elizabeth R Stirling; David R Soto-Pantoja
Journal:  Methods Mol Biol       Date:  2022

7.  Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.

Authors:  Susanne M Steggerda; Mark K Bennett; Jason Chen; Ethan Emberley; Tony Huang; Julie R Janes; Weiqun Li; Andrew L MacKinnon; Amani Makkouk; Gisele Marguier; Peter J Murray; Silinda Neou; Alison Pan; Francesco Parlati; Mirna L M Rodriguez; Lee-Ann Van de Velde; Tracy Wang; Melissa Works; Jing Zhang; Winter Zhang; Matthew I Gross
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

8.  Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation.

Authors:  David J Klinke; Qing Wang
Journal:  Front Pharmacol       Date:  2017-01-04       Impact factor: 5.810

9.  Whole Genome Expression Microarray Analysis of Highly Versus Poorly Tumorigenic Murine Melanoma Cell Lines Provides Insights into Factors That Regulate Tumor Growth, Metastasis, and Immunogenicity.

Authors:  Kristian Michael Hargadon
Journal:  Front Immunol       Date:  2015-09-14       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.